Daunorubicin reduces cardiomyopathy risk compared with doxorubicin in childhood cancer survivors

Daunorubicin appeared associated with a lower cardiomyopathy risk than doxorubicin among childhood cancer survivors, according to a multicenter cohort study published in JAMA Oncology.

Read more: https://www.healio.com/hematology-oncology/pediatric-oncology/news/in-the-journals/%7Bc480352e-3ab4-42b1-b33e-4e049f3371b3%7D/daunorubicin-reduces-cardiomyopathy-risk-compared-with-doxorubicin-in-childhood-cancer-survivors